Population pharmacokinetics of liposomal irinotecan in patients with cancer and exposure–safety analyses in patients with metastatic pancreatic cancer

Liposomal irinotecan is a liposomal formulation of irinotecan, which prolongs circulation of irinotecan and its active metabolite SN‐38. A population pharmacokinetic (PK) model was developed based on data from seven studies (N = 440). Adequacy of the model was assessed using multiple methods, includ...

Descripción completa

Detalles Bibliográficos
Autores principales: Brendel, Karl, Bekaii‐Saab, Tanios, Boland, Patrick M, Dayyani, Farshid, Dean, Andrew, Macarulla, Teresa, Maxwell, Fiona, Mody, Kabir, Pedret‐Dunn, Anna, Wainberg, Zev A, Zhang, Bin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8674005/
https://www.ncbi.nlm.nih.gov/pubmed/34750990
http://dx.doi.org/10.1002/psp4.12725

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8674005/
https://www.ncbi.nlm.nih.gov/pubmed/34750990
http://dx.doi.org/10.1002/psp4.12725

Ejemplares similares